search
Back to results

Randomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward (IM-OK-FAST)

Primary Purpose

Psychomotor Agitation, Psychiatric Disorder, Emergency Psychiatric

Status
Completed
Phase
Phase 4
Locations
Argentina
Study Type
Interventional
Intervention
Ketamine
Sponsored by
Universidad Nacional de Rosario
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Psychomotor Agitation focused on measuring Psychomotor agitation; Tranquilizing agents

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • signs of agitation,
  • age between 18 and 64 years,
  • bipolar (maniac or mixed episode)
  • psychotic disorder diagnosis
  • disorders due to drug abuse,
  • organic disorder,
  • anxiety or personality disorder
  • Overt Agitation Severity Scale Total Score (OASS) equal or greater than 20
  • Overt Aggressive Scale (OAS) with four or more positive items.

Exclusion Criteria:

  • failure to agree to participate in the study,
  • incapability of completing all steps
  • unstable clinical disease -
  • pregnancy

Sites / Locations

  • hospital Larcade

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

ketamine

olanzapine

Arm Description

assessment of agitation status with Ramsay Sedation Scale administration of ketamine 10 mg / ml IM one dose supervision of vital signs registration of time of ketamine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of ketamine administration) withdrawal of patient from the study if other medication was needed (aside of ketamine)

assessment of agitation status with Ramsay Sedation Scale administration of olanzapine 10 mg / ml IM one dose supervision of vital signs registration of time of olanzapine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of olanzapine administration) withdrawal of patient from the study if other medication was needed (aside of olanzapine)

Outcomes

Primary Outcome Measures

sedation status
subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after administration of the medication with Ramsay Sedation Scale score (RSS).

Secondary Outcome Measures

adverse effects
extrapirarmidal effects with Angus Scale for extrapiramidal movements excessive sedation with Ramsay Sedation Scale score paradoxical agitation with Ramsay Sedation Scale Score

Full Information

First Posted
July 10, 2017
Last Updated
July 11, 2017
Sponsor
Universidad Nacional de Rosario
search

1. Study Identification

Unique Protocol Identification Number
NCT03216941
Brief Title
Randomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward
Acronym
IM-OK-FAST
Official Title
Prospective Randomised Double Blind Trial of Ketiapine and Olanzapine Comparative Efficacy for Fast Sedation of Severely Agitated Patients in Emergency Psychiatric Ward
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
January 1, 2015 (Actual)
Primary Completion Date
January 1, 2016 (Actual)
Study Completion Date
January 31, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad Nacional de Rosario

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
comparison of intramuscular olanzapine and ketamine efficacy as first medication for fast sedation of patients with agitation and aggressive behavior. Five hundred patients with agitation caused by psychiatric disorder were randomly assigned under double-blind conditions to receive olanzapine or ketiapine. The Overt Agitation Severity Scale, Overt Aggression Scale and Ramsay Sedation Scale will be applied within 12 hours after the first dosage.
Detailed Description
double-blind controlled trial to compare effectiveness of intramuscular olanzapine and ketamine as first medication to fast sedation of patients with agitation caused by psychiatric conditions. Randomization will be performed by permuted blocks allocation in which ketiamine or olanzapine standard treatment will be assigned to blocks of five patients and distributed in this order: olanzapine and ketiamine. This assignment will be repeated until the total number of subjects (500) be reached. agitation status will be operationalized using Overt Agitation Severity Scale Total Score (OASS) equal or greater than 20 and Overt Aggressive Scale (OAS) with four or more positive items. Full physical and neurological examination will be completed as soon as possible, whenever patient is considered eligible for the study. Written Informed consent should be provided before and after participating in this study, and should be reviewed and approved by the institutional review board. Written consent obtained before admission to the emergency ward by legal guardian and after 12 hours by the patient (whenever he or she is is able to understand the information) or by the guardian. This study will comply with principles of the Declaration of Helsinki and Good Clinical Practice and approved by the Institutional Review Board (IRB) of Hospital Larcade of San Miguel County (Province of Buenos AIres (Project msm001) inter-rater reproducibility will be evaluated by two raters which will repeatedly apply OASS, OAS and RSS to patients admitted to the emergency room before the study until the intraclass correlation coefficient (ICC) reach a score of 0.80 or greater medications will be packaged in identical color-coded boxes and dosage of of olanzapine and ketiamine will be determined according to standard protocols and previous studies. If a subject needs another intervention will be removed from the study. subjects will be assessed from 1 to 12 hours after administration of selected medication. psychiatrists will be masked to patient's treatment assignment, and patients will be instructed not to reveal current treatment to investigators. clinical safety of treatment will be assessed by notification and with an close-ended inquiry into adverse events together with full physical examination and vital signs measurements. Statistical analyses mean and standard deviation (SD) and comparisons of baseline demographic and clinical characteristics with one-way analysis of variance (ANOVA), chi-square test for categorical variables and mixed-effect analyses of covariance (ANCOVAs) with medication (olanzapine, ketiamine) as between-groups factor and time (1 hour, 2 hours, 4 hours, 6 hours and 12 hours) as a within-group factor. OASS at time zero, OAS at time zero, and presence of excessive sedation will be fixe covariates, and symptom ratings (OASS, OAS and RSS) will be time-varying covariates. differences between groups at each time point and variance with post-hoc Duncan's tests will be calculated to compare mean OASS, OAS and RSS scores between groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psychomotor Agitation, Psychiatric Disorder, Emergency Psychiatric, Tranquilizers
Keywords
Psychomotor agitation; Tranquilizing agents

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
double-blind controlled trial to compare the effectiveness of intramuscular olanzapine and ketamine as first medication(s) used to treat patients with agitation caused by psychosis.
Masking
Care Provider
Masking Description
care provider were masked with regard to the patient's treatment assignment, and patients were instructed not to reveal their current treatment to the investigators.
Allocation
Randomized
Enrollment
500 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ketamine
Arm Type
Active Comparator
Arm Description
assessment of agitation status with Ramsay Sedation Scale administration of ketamine 10 mg / ml IM one dose supervision of vital signs registration of time of ketamine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of ketamine administration) withdrawal of patient from the study if other medication was needed (aside of ketamine)
Arm Title
olanzapine
Arm Type
Active Comparator
Arm Description
assessment of agitation status with Ramsay Sedation Scale administration of olanzapine 10 mg / ml IM one dose supervision of vital signs registration of time of olanzapine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of olanzapine administration) withdrawal of patient from the study if other medication was needed (aside of olanzapine)
Intervention Type
Drug
Intervention Name(s)
Ketamine
Other Intervention Name(s)
olanzapine
Intervention Description
study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study. All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication.
Primary Outcome Measure Information:
Title
sedation status
Description
subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after administration of the medication with Ramsay Sedation Scale score (RSS).
Time Frame
1 to 12 hours
Secondary Outcome Measure Information:
Title
adverse effects
Description
extrapirarmidal effects with Angus Scale for extrapiramidal movements excessive sedation with Ramsay Sedation Scale score paradoxical agitation with Ramsay Sedation Scale Score
Time Frame
1 to 24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: signs of agitation, age between 18 and 64 years, bipolar (maniac or mixed episode) psychotic disorder diagnosis disorders due to drug abuse, organic disorder, anxiety or personality disorder Overt Agitation Severity Scale Total Score (OASS) equal or greater than 20 Overt Aggressive Scale (OAS) with four or more positive items. Exclusion Criteria: failure to agree to participate in the study, incapability of completing all steps unstable clinical disease - pregnancy
Facility Information:
Facility Name
hospital Larcade
City
San Miguel
State/Province
Buenos Aires
ZIP/Postal Code
1405
Country
Argentina

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
make accesible patients data on SPSS file formats with not personal ID data

Learn more about this trial

Randomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward

We'll reach out to this number within 24 hrs